45TiP A randomized, molecular driven phase II trial of carboplatin-paclitaxel-bev vs carboplatin-paclitaxel-bev-rucaparib vs carboplatin-paclitaxel-rucaparib, selected according to HRD status, in patients with advanced ovarian cancer

Autor:	G. Scambia, V. Salutari, L. Musacchio, S. Siena, S. Pignata, L. Zavallone, G. Valabrega, G. Cormio, A.M. Mosconi, C. Ricci, V. Ghizzoni, M.V. Carbone, E. Giudice, F. Camarda, C. Nero, F. Tronconi, D. Lorusso
Rok vydání:	2022
Předmět:	Oncology Hematology
Zdroj:	Annals of Oncology. 33:S401
ISSN:	0923-7534
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::12df5ee6e2c9e586f693a6bd6b02d82b https://doi.org/10.1016/j.annonc.2022.04.063 Zobrazit plný text záznamu